Total Payments
$11,194
2023 Payments
$28.38
Companies
4
Transactions
25
Medicare Patients
1,420
Medicare Billing
$354,649
Payment Breakdown by Category
Other$9,700 (86.7%)
Travel$762.77 (6.8%)
Food & Beverage$679.38 (6.1%)
Education$52.27 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,700 | 9 | 86.7% |
| Travel and Lodging | $762.77 | 3 | 6.8% |
| Food and Beverage | $679.38 | 8 | 6.1% |
| Education | $52.27 | 5 | 0.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Allergan Inc. | $10,995 | 18 | $0 (2018) |
| Shionogi Inc | $120.44 | 2 | $0 (2022) |
| Merck Sharp & Dohme Corporation | $50.80 | 4 | $0 (2020) |
| ViiV Healthcare Company | $28.38 | 1 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $28.38 | 1 | ViiV Healthcare Company ($28.38) |
| 2022 | $120.44 | 2 | Shionogi Inc ($120.44) |
| 2020 | $38.10 | 3 | Merck Sharp & Dohme Corporation ($38.10) |
| 2019 | $12.70 | 1 | Merck Sharp & Dohme Corporation ($12.70) |
| 2018 | $3,273 | 4 | Allergan Inc. ($3,273) |
| 2017 | $7,722 | 14 | Allergan Inc. ($7,722) |
All Payment Transactions
25 individual payment records from CMS Open Payments
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/22/2023 | ViiV Healthcare Company | CABENUVA (Biological) | Food and Beverage | In-kind items and services | $28.38 | General |
| Category: HIV | ||||||
| 05/04/2022 | Shionogi Inc | Fetroja (Drug) | Food and Beverage | In-kind items and services | $118.97 | General |
| Category: Infections and Infectious Diseases | ||||||
| 02/11/2022 | Shionogi Inc | Fetroja (Drug) | Education | In-kind items and services | $1.47 | General |
| Category: Infections and Infectious Diseases | ||||||
| 03/05/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 02/10/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 01/03/2020 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 12/16/2019 | Merck Sharp & Dohme Corporation | ZERBAXA (Drug) | Education | In-kind items and services | $12.70 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/19/2018 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/19/2018 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/19/2018 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $72.75 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/19/2018 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 10/18/2017 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 06/01/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $418.14 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/17/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $14.76 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/10/2017 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/10/2017 | Allergan Inc. | AVYCAZ (Drug) | Food and Beverage | In-kind items and services | $16.37 | General |
| Category: ANTI-INFECTIVE | ||||||
| 05/03/2017 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/28/2017 | Allergan Inc. | DALVANCE (Drug) | Food and Beverage | In-kind items and services | $3.79 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/01/2017 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,500.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/01/2017 | Allergan Inc. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $445.40 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/01/2017 | Allergan Inc. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $305.65 | General |
| Category: ANTI-INFECTIVE | ||||||
| 04/01/2017 | Allergan Inc. | AVYCAZ (Drug) | Travel and Lodging | In-kind items and services | $11.72 | General |
| Category: ANTI-INFECTIVE | ||||||
| 03/07/2017 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
| 02/06/2017 | Allergan Inc. | TEFLARO (Drug) | Food and Beverage | In-kind items and services | $6.22 | General |
| Category: ANTI-INFECTIVE | ||||||
| 01/26/2017 | Allergan Inc. | AVYCAZ (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $200.00 | General |
| Category: ANTI-INFECTIVE | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 385 | 1,390 | $219,215 | $95,882 |
| 2022 | 7 | 339 | 1,131 | $190,075 | $75,636 |
| 2021 | 7 | 340 | 1,345 | $233,503 | $93,034 |
| 2020 | 5 | 356 | 1,300 | $233,176 | $90,098 |
Total Patients
1,420
Total Services
5,166
Medicare Billing
$354,649
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99308 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 15 minutes | Facility | 2023 | 98 | 716 | $93,080 | $42,850 | 46.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 63 | 382 | $57,300 | $24,258 | 42.3% |
| 99306 | Initial nursing facility care with high level of medical decision making, per day, if using time, at least 45 minutes | Facility | 2023 | 69 | 71 | $21,300 | $10,414 | 48.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 37 | 41 | $14,760 | $5,203 | 35.3% |
| 99305 | Initial nursing facility care with moderate level of medical decision making, per day, if using time, at least 35 minutes | Facility | 2023 | 36 | 38 | $8,550 | $4,084 | 47.8% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 19 | 32 | $7,200 | $2,980 | 41.4% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 24 | 25 | $7,250 | $2,526 | 34.8% |
| 99307 | Subsequent nursing facility care with straightforward level of medical decision making, per day, if using time, at least 10 minutes | Facility | 2023 | 28 | 68 | $6,800 | $2,166 | 31.9% |
| 99309 | Subsequent nursing facility care with moderate level of medical decision making, per day, if using time, at least 30 minutes | Facility | 2023 | 11 | 17 | $2,975 | $1,399 | 47.0% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 91 | 603 | $90,450 | $34,673 | 38.3% |
| 99308 | Follow-up nursing facility visit per day, typically 15 minutes | Facility | 2022 | 52 | 286 | $37,275 | $15,891 | 42.6% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 49 | 51 | $18,360 | $7,747 | 42.2% |
| 99306 | Initial nursing facility visit per day, typically 45 minutes | Facility | 2022 | 52 | 52 | $15,600 | $6,915 | 44.3% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 43 | 46 | $13,340 | $4,924 | 36.9% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 30 | 46 | $10,350 | $3,824 | 36.9% |
| 99307 | Follow-up nursing facility visit per day, typically 10 minutes | Facility | 2022 | 22 | 47 | $4,700 | $1,662 | 35.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 120 | 1,050 | $157,500 | $61,714 | 39.2% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 92 | 100 | $36,000 | $15,982 | 44.4% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 45 | 79 | $17,775 | $6,691 | 37.6% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 37 | 39 | $11,310 | $4,348 | 38.4% |
| 99305 | Initial nursing facility visit, typically 35 minutes per day | Facility | 2021 | 15 | 16 | $3,600 | $1,700 | 47.2% |
| 99308 | Subsequent nursing facility visit, typically 15 minutes per day | Facility | 2021 | 11 | 27 | $3,510 | $1,530 | 43.6% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 20 | 34 | $3,808 | $1,070 | 28.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 141 | 1,013 | $151,950 | $57,289 | 37.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 110 | 128 | $46,080 | $20,211 | 43.9% |
About Dr. Muhammad Motiwala, MD
Dr. Muhammad Motiwala, MD is a Internal Medicine healthcare provider based in Tomball, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/12/2010. The National Provider Identifier (NPI) number assigned to this provider is 1447576707.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Muhammad Motiwala, MD has received a total of $11,194 in payments from pharmaceutical and medical device companies, with $28.38 received in 2023. These payments were reported across 25 transactions from 4 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($9,700).
As a Medicare-enrolled provider, Motiwala has provided services to 1,420 Medicare beneficiaries, totaling 5,166 services with total Medicare billing of $354,649. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Tomball, TX
- Active Since 04/12/2010
- Last Updated 09/12/2023
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1447576707
Products in Payments
- AVYCAZ (Drug) $10,985
- Fetroja (Drug) $120.44
- ZERBAXA (Drug) $50.80
- CABENUVA (Biological) $28.38
- TEFLARO (Drug) $6.22
- DALVANCE (Drug) $3.79
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Tomball
Muhammad Irfan, M.d, M.D
Internal Medicine — Payments: $56,330
Internal Medicine $56,330
Shamaila Aslam, Md, MD
Internal Medicine — Payments: $23,675
Internal Medicine $23,675
Imran Nathani, Md, MD
Internal Medicine — Payments: $10,265
Internal Medicine $10,265
Dr. Mark Le, M.d, M.D
Internal Medicine — Payments: $7,042
Internal Medicine $7,042
Dr. S Janel Beatie, Md, MD
Internal Medicine — Payments: $6,378
Internal Medicine $6,378
Amanbir Sohal, M.d, M.D
Internal Medicine — Payments: $6,139
Internal Medicine $6,139